Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Ther
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Ther
Shareholder Alert: Robbins LLP Informs Investors of the Sarepta Therapeutics, Inc. Class Action
07:28pm, Monday, 30'th Jun 2025
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASD
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:26pm, Monday, 30'th Jun 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previously app
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
04:17pm, Monday, 30'th Jun 2025
LOS ANGELES , June 30, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarep
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) INVESTOR ALERT: Investors With Large Losses in Sarepta Therapeutics, Inc. Should Contact Bernstein Liebhard LLP
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
10:00am, Saturday, 28'th Jun 2025
NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such
NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Ther
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
05:59pm, Friday, 27'th Jun 2025
NEW YORK , June 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therap
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Sarepta Therapeutics, I
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT)
03:04pm, Friday, 27'th Jun 2025
NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of N
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Sarepta business and prospects, resulting in its stock trading at inflated prices.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
10:00am, Friday, 27'th Jun 2025
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are
2 Beaten-Down Stocks to Avoid
08:15am, Friday, 27'th Jun 2025
Over the past year, Editas Medicine (EDIT -3.20%) and Sarepta Therapeutics (SRPT -1.38%), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatili
